Quantum Pharma plc (LON:QP), the service-led niche pharmaceutical developer and supplier to the health and care sectors, has reported its Preliminary financial results for the 12 months to January 31,
County Durham based Quantum Pharma has bolstered its executive team with the help of business advisers UNW. The niche pharmaceutical developer and manufacturer, which supplies a range of innovative products
Niche pharma firm Quantum Pharma says it is on target to meet market expectations after taking action to tighten its focus. The Burnopfield pharmaceutical developer , manufacturer and supplier issued
Quantum Pharma plc (LON:QP), the service-led niche pharmaceutical manufacturer, developer and supplier to the health and care sectors, has released a pre-close trading update this morning. Zeus Capital said: The
Quantum Pharma Plc (AIM: QP.), the service-led niche pharmaceutical developer, manufacturer and supplier to the health and care sectors, announces that on 3 January 2017 the Company was notified that
TR-1: NOTIFICATION OF MAJOR INTEREST IN SHARES 1. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attached: Quantum Pharma plc 2 Reason
Quantum Pharma plc (AIM: QP.) announced this morning a proposed fundraising up to £15 million, by way of the conditional placing of up to 44,117,647 Placing Shares at a price
Zeus Capital’s Gary Waanders discusses Quantum Pharma PLC in this exclusive interview with DirectorsTalk
Quantum Pharma Plc (LON:QP) is the topic of conversation when Dr Gary Waanders the Director of Healthcare Research at Zeus Capital caught up with DirectorsTalk to discuss interim results. Gary
Chris Rigg, Chief Financial Officer and Acting Chief Executive Officer of Quantum Pharma LON:QP., commented: “The core specials business is performing well and launches from the Niche Pharmaceuticals pipeline are
© 2024 – DirectorsTalk. All rights reserved. Reproduction in whole or in part, in any form or medium without express written permission is prohibited.
